Shandong Weigao Group Medical Polymer Company Limited
Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, wholesale, and sale of medical devices in the People's Republic of China and internationally. It operates through Medical Device Products, Orthopedic Products, Pharma Packaging Products, Interventional Products, Blood Management Products, and Others segments. The company's medical device pro… Read more
Shandong Weigao Group Medical Polymer Company Limited (UK2) - Net Assets
Latest net assets as of June 2025: €25.69 Billion EUR
Based on the latest financial reports, Shandong Weigao Group Medical Polymer Company Limited (UK2) has net assets worth €25.69 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€36.14 Billion) and total liabilities (€10.45 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €25.69 Billion |
| % of Total Assets | 71.09% |
| Annual Growth Rate | 9.8% |
| 5-Year Change | 37.8% |
| 10-Year Change | 134.93% |
| Growth Volatility | 3.29 |
Shandong Weigao Group Medical Polymer Company Limited - Net Assets Trend (2013–2024)
This chart illustrates how Shandong Weigao Group Medical Polymer Company Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shandong Weigao Group Medical Polymer Company Limited (2013–2024)
The table below shows the annual net assets of Shandong Weigao Group Medical Polymer Company Limited from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €25.34 Billion | +5.62% |
| 2023-12-31 | €23.99 Billion | +2.33% |
| 2022-12-31 | €23.45 Billion | +12.14% |
| 2021-12-31 | €20.91 Billion | +13.69% |
| 2020-12-31 | €18.39 Billion | +8.20% |
| 2019-12-31 | €17.00 Billion | +11.89% |
| 2018-12-31 | €15.19 Billion | +11.34% |
| 2017-12-31 | €13.64 Billion | +11.79% |
| 2016-12-31 | €12.21 Billion | +13.15% |
| 2015-12-31 | €10.79 Billion | +9.18% |
| 2014-12-31 | €9.88 Billion | +9.01% |
| 2013-12-31 | €9.06 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shandong Weigao Group Medical Polymer Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 224.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €19.85 Billion | 83.58% |
| Other Components | €3.90 Billion | 16.42% |
| Total Equity | €23.75 Billion | 100.00% |
Shandong Weigao Group Medical Polymer Company Limited Competitors by Market Cap
The table below lists competitors of Shandong Weigao Group Medical Polymer Company Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TMC the metals company Inc
NASDAQ:TMC
|
$1.27 Billion |
|
Kimbell Royalty Partners LP
NYSE:KRP
|
$1.27 Billion |
|
Zhejiang Changsheng Sliding Bearings Co Ltd Class A
SHE:300718
|
$1.27 Billion |
|
GRUPO COM.CHEDRAUI B CL.I
F:2GCB
|
$1.27 Billion |
|
JCDecaux SA
PINK:JCDXF
|
$1.27 Billion |
|
MONETA Money Bank a.s
OTCGREY:GMYYF
|
$1.27 Billion |
|
Mobileye Global Inc. Class A Common Stock
NASDAQ:MBLY
|
$1.27 Billion |
|
YOUZU Interactive Co Ltd
SHE:002174
|
$1.27 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shandong Weigao Group Medical Polymer Company Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 22,449,121,000 to 23,751,643,000, a change of 1,302,522,000 (5.8%).
- Net income of 2,066,668,000 contributed positively to equity growth.
- Dividend payments of 870,588,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €2.07 Billion | +8.7% |
| Dividends Paid | €870.59 Million | -3.67% |
| Other Changes | €136.88 Million | +0.58% |
| Total Change | €- | 5.80% |
Book Value vs Market Value Analysis
This analysis compares Shandong Weigao Group Medical Polymer Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.10x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €2.95 | €0.52 | x |
| 2018-12-31 | €3.21 | €0.52 | x |
| 2019-12-31 | €3.58 | €0.52 | x |
| 2020-12-31 | €3.88 | €0.52 | x |
| 2021-12-31 | €4.26 | €0.52 | x |
| 2022-12-31 | €4.74 | €0.52 | x |
| 2023-12-31 | €4.91 | €0.52 | x |
| 2024-12-31 | €5.27 | €0.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shandong Weigao Group Medical Polymer Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.70%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.79%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.46x
- Recent ROE (8.70%) is below the historical average (10.25%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 4.29% | 8.41% | 0.41x | 1.25x | €-516.05 Million |
| 2014 | 11.02% | 20.56% | 0.44x | 1.23x | €100.16 Million |
| 2015 | 10.44% | 18.80% | 0.44x | 1.27x | €46.92 Million |
| 2016 | 9.32% | 16.43% | 0.43x | 1.33x | €-80.72 Million |
| 2017 | 12.97% | 27.49% | 0.37x | 1.26x | €396.11 Million |
| 2018 | 10.15% | 16.72% | 0.37x | 1.65x | €21.48 Million |
| 2019 | 11.40% | 17.80% | 0.39x | 1.63x | €226.37 Million |
| 2020 | 11.57% | 17.89% | 0.41x | 1.56x | €275.60 Million |
| 2021 | 11.65% | 17.07% | 0.43x | 1.58x | €318.07 Million |
| 2022 | 12.57% | 20.00% | 0.41x | 1.53x | €556.42 Million |
| 2023 | 8.92% | 15.13% | 0.39x | 1.50x | €-243.01 Million |
| 2024 | 8.70% | 15.79% | 0.38x | 1.46x | €-308.50 Million |
Industry Comparison
This section compares Shandong Weigao Group Medical Polymer Company Limited's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $7,400,595,711
- Average return on equity (ROE) among peers: 4.58%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shandong Weigao Group Medical Polymer Company Limited (UK2) | €25.69 Billion | 4.29% | 0.41x | $1.27 Billion |
| Modern Dental Group Limited (1MD) | $2.36 Billion | 15.30% | 0.55x | $213.74 Million |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $709.04 Million | 17.68% | 0.69x | $475.06 Million |
| Alcon Inc. (2U3) | $19.26 Billion | 1.95% | 0.45x | $32.92 Billion |
| Shofu Inc. (69W) | $35.51 Billion | 8.83% | 0.23x | $217.64 Million |
| 7VG (7VG) | $176.36 Million | 14.92% | 1.12x | $658.78 Million |
| Bio-gate AG (BIG1) | $4.25 Million | -42.46% | 0.46x | $2.79 Million |
| Paul Hartmann AG (PHH2) | $690.37 Million | 10.65% | 0.81x | $783.58 Million |
| Sartorius AG VZO O.N. (SRT) | $497.08 Million | 9.76% | 1.56x | $6.63 Billion |